Key facts
- Notable investors include Hongfeng Capital, Huayi Brothers Media, Livzon Pharmaceutical Group, Panlin Capital, Qiaojing Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for L&L Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for L&L Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About L&L Bio
Developer and researcher of biomacromolecule drugs designed to improve tumor immunotherapy. The company's drugs include monoclonal antibodies, bispecific antibody drugs, and other tumor immunotherapy products, providing the healthcare industry with biomedical products and therapies to meet the actual needs of cancer patients.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2015
- Employees
- 9
- Website
- lnlbio.com/
- Ownership
- Privately Held (backing)
L&L Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in L&L Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on L&L Bio in its N-PORT filings yet. We sweep new filings monthly.